Mentioned:
No items found.
No items found.
No items found.
The next frontier for OpenAI might be longevity. But, why?
What’s happening:
- OpenAI has developed a new artificial intelligence model known as GPT-4b in partnership with longevity science startup Retro Biosciences
The big idea:
- GPT-4b is purpose built to re-engineer proteins such as Yamanaka factors to improve how efficiently stem cells are produced
- GPT-4b was trained on protein sequences from multiple different species and is largely focused on protein interactions and modifications
Why it matters:
- Leveraging artificial intelligence for longevity research could unlock massive new breakthroughs, in large part due to the ability for artificial intelligence models to be trained on large amounts highly specific scientific research and detect patterns that have yet to be discovered through traditional clinical studies
Going deeper:
- OpenAI co-founder Sam Altman is also a major backer of Retro Biosciences, previously investing $180M USD into the company to accelerate their research around extending human life expectancy
The intrigue:
- OpenAI has been expanding into multiple new areas lately, including a new major push into robotics
